title: Cyclin-dependent kinase inhibitors closer to market launch?
abstract: BACKGROUND
  Interest in cyclin-dependent kinase (CDK) inhibitors was stimulated by the demonstration that their pharmacological activities could lead to therapies for numerous diseases. Until now, despite the clinical introduction of a dozen compounds belonging to other classes of kinase inhibitors, no CDK inhibitor has reached the marketplace.
  
  
  METHODS
  This review covers CDK inhibitor patents published between 2009 and September 2012. It presents compounds currently undergoing clinical development, along with our earlier (2010) review of the same topic, as well as descriptions of recently published compounds not disclosed in the patent literature. It provides the reader with an update of all chemical structures of current interest in the CDK inhibitor field.
  
  
  CONCLUSIONS
  Though cancer remains the most obvious application for CDK inhibition, other indications, such as HIV infection, could potentially be treated with CDK inhibitors.
authors.affiliation: Laboratoire de Chimie Organique 2, INSERM U 1022, Université Paris - Descartes, 4 avenue de l'Observatoire, 75270 Paris cedex 06, France. herve.galons@univ-paris5.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Galons
authors.forename: Nassima
authors.initials: N
authors.lastname: Oumata
authors.forename: Olfa
authors.initials: O
authors.lastname: Gloulou
authors.forename: Laurent
authors.initials: L
authors.lastname: Meijer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D010330:Patents as Topic
chemical_list: D000970:Antineoplastic Agents; D018844:Cyclin-Dependent Kinases